The Blood Cancer Landscape Report
The Report Offers Insight Into:
- The Clinical Trial Landscape: Leukemia & non-Hodgkin lymphoma drive the highest clinical trial activity due to prevalence, complexity, and unmet need
- Drug Development Pipelines & Targets: Cell therapies dominate pipelines, while CD19 is the most investigated target
- Recent FDA Approvals: Approvals span diverse modalities, including a bispecific antibody, menin inhibitor, and CD19 CAR-T therapy
- Targets Attracting Investments: Deal-making remains strong around B-cell targets (CD3, CD20), while emerging bispecifics and trispecifics attract investor interest
You May Also Be Interested In…
Learn More About Oncology
What is Beacon Oncology?
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
